Drugs for Melanoma

Table. Drugs Prescribed for Melanoma

• Drug name (generic name)
• Drug company
• Indications
• Patient support services

Drug name (generic name)
• Braftovi (encorafenib) + Mektovi (binimetinib)
Drug company
• Pfizer
Indication
• Treatment of unresectable or metastatic melanoma and a BRAF V600E or V600K mutation, as detected by an FDA-approved test
Patient support services
• Pfizer Oncology Together Co-Pay Savings Program
  877-744-5675
  
  Pfizer Patient Assistance Program
  877-744-5675

Drug name (generic name)
• Cotellic (cobimetinib) Tablets
Drug company
• Genentech
Indication
• Treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with Zelboraf
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Imlygic (talimogene laherparepvec)
Drug company
• Amgen
Indication
• Treatment of unresectable melanoma
Patient support services
• Amgen Support Co-Pay Program
  866-264-2778
  
  Amgen Safety Net Foundation
  866-264-2778

Drug name (generic name)
• Keytruda (pembrolizumab)
Drug company
• Merck
Indication
• Treatment of unresectable or metastatic melanoma
  
  Adjuvant treatment of patients aged 12 or older with stage IIB, IIC, or III melanoma, after complete resection
Patient support services
• Merck Co-pay Assistance Program
  855-257-3932
  
  Merck Patient Assistance Program
  855-257-3932

Drug name (generic name)
• Kimmtrak (tebentafusp-tebn)
Drug company
• Immunocore
Indication
• Treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma
Patient support services
• Kimmtrak Connect
  844-775-2273

Drug name (generic name)
• Mekinist (trametinib) Tablets
Drug company
• Novartis
Indication
• Treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutation, as a single agent or in combination with Tafinlar
  
  Adjuvant treatment, in combination with Tafinlar, for patients with melanoma and a BRAF V600E or V600K mutation, and involvement of lymph node(s), after complete resection
Patient support services
• Novartis Oncology Universal Co-pay Program
  877-577-7756
  
  Novartis Patient Assistance Foundation
  800-277-2254

Drug name (generic name)
• Opdivo (nivolumab)
Drug company
• Bristol Myers Squibb
Indication
• Treatment of unresectable or metastatic melanoma, as a single agent or in combination with Yervoy
  
  Treatment of melanoma with lymph node involvement or metastatic melanoma after complete resection in the adjuvant setting
Patient support services
• BMS Oncology Co-Pay Assistance Program
  800-861-0048
  
  Bristol Myers Squibb Patient Assistance Foundation
  800-736-0003

Drug name (generic name)
• Opdualag (nivolumab and relatlimab-rmbw)
Drug company
• Bristol Myers Squibb
Indication
• Treatment of patients ≥12 years of age with unresectable or metastatic melanoma
Patient support services
• BMS Oncology Co-Pay Assistance Program
  800-861-0048
  
  Bristol Myers Squibb Patient Assistance Foundation
  800-736-0003

Drug name (generic name)
• Tafinlar (dabrafenib) Capsules
Drug company
• Novartis
Indication
• Treatment of unresectable or metastatic melanoma with BRAF V600E mutation, as a single agent or in combination with Mekinist
  
  Adjuvant treatment, in combination with Mekinist, for patients with melanoma and a BRAF V600E or V600K mutation, and involvement of lymph node(s), after complete resection
Patient support services
• Novartis Oncology Universal Co-pay Program
  877-577-7756
  
  Novartis Patient Assistance Foundation
  800-277-2254

Drug name (generic name)
• Tecentriq (atezolizumab)
Drug company
• Genentech
Indication
• Treatment, in combination with cobimetinib and vemurafenib, of unresectable or metastatic melanoma with BRAF V600 mutation
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Yervoy (ipilimumab)
Drug company
• Bristol Myers Squibb
Indication
• Treatment of unresectable or metastatic melanoma in patients 12 years or older
  
  Treatment, in combination with Opdivo, of adults with unresectable or metastatic melanoma
  
  Adjuvant treatment of cutaneous melanoma with pathologic involvement of regional lymph nodes in patients with complete resection, including total lymphadenectomy
Patient support services
• BMS Oncology Co-Pay Assistance Program
  800-861-0048
  
  Bristol Myers Squibb Patient Assistance Foundation
  800-736-0003

Drug name (generic name)
• Zelboraf (vemurafenib)
Drug company
• Genentech
Indication
• Unresectable or metastatic melanoma
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331